バイオ医薬品添加剤は、医学的に有効な成分を用いて方法論的に調製されたレシピエントのシステムでさらにドラッグデリバリーを処理する不活性ドラッグデリバリー物質です。添加剤は安定しており、再現性があり、薬理学的に不活性であり、費用対効果も高くなります。それらは、トウモロコシ、小麦、砂糖、ミネラル、およびその他の物質で構成されています。バイオ医薬品添加剤の剤型としては、カプセル、塗り薬、錠剤、ゲル、注射剤、経皮パッチなど、さまざまな種類があります。さらに、このような添加剤は、強力な成分の正確な投与が可能で、成分に機械的強度を与え、有効成分の表面積を増やし、環境反応から薬剤を保護し、薬剤の質感、におい、味を隠します。
パンデミックの発生時に医薬品の生産が増加したことによって、政府の政策を後押しし、生産コストを最小限に抑える部分的な補助金制度が導入されたため、バイオ医薬品添加剤の需要が拡大しています。世界中でコロナウイルスが発生したことから、特殊医薬品の需要が増加した結果、添加剤の売上がさらに拡大しました。メーカーは、ショ糖、塩化ナトリウム、塩化マグネシウム六水和物、および二ナトリウムエデト酸二ナトリウムで構成されるバイオ医薬品用の特定の添加剤を供給しています。 さらに、慢性疾患と診断される患者の増加が、バイオ医薬品添加剤メーカーの可能性を生み出しています。上記の要因が市場の成長を促し、予測期間中はそれが加速すると予想されます。
調査対象
TABLE OF CONTENTS
1. REPORT PROLOGUE
2. MARKET INTRODUCTION
2.1. Definition
2.2. Scope of the Study
2.2.1. Research Objective
2.2.2. Assumptions
2.2.3. Limitations
3. RESEARCH METHODOLOGY
3.1. Overview
3.2. Data Mining
3.3. Secondary Research
3.4. Primary Research
3.4.1. Primary Interviews and Information Gathering Process
3.4.2. Breakdown of Primary Respondents
3.5. Forecasting Cellulite Type
3.6. Market Size Estimation
3.6.1. Bottom-Up Approach
3.6.2. Top-Down Approach
3.7. Data Triangulation
3.8. Validation
4. MARKET DYNAMICS
4.1. Overview
4.2. Drivers
4.3. Restraints
4.4. Opportunities
5. MARKET FACTOR ANALYSIS
5.1. Porter’s Five Forces Analysis
5.1.1. Bargaining Power of Suppliers
5.1.2. Bargaining Power of Buyers
5.1.3. Threat of New Entrants
5.1.4. Threat of Substitutes
5.1.5. Intensity of Rivalry
5.2. Value Chain Analysis
5.3. COVID-19 Impact Analysis
5.3.1. Market Impact Analysis
5.3.2. Impact on Supply Chain
5.3.3. Regional Impact
5.3.4. Opportunity and Threat Analysis
6. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET, BY PRODUCT
6.1. Overview
6.2. Solubilizers & Surfactants/Emulsifiers
Market Estimates & Forecast, by Region, 2018-2027
Market Estimates & Forecast, by Country, 2018-2027
6.2.1. Triglycerides
Market Estimates & Forecast, by Region, 2018-2027
Market Estimates & Forecast, by Country, 2018-2027
6.2.2. Esters
Market Estimates & Forecast, by Region, 2018-2027
Market Estimates & Forecast, by Country, 2018-2027
6.2.3. Others
Market Estimates & Forecast, by Region, 2018-2027
Market Estimates & Forecast, by Country, 2018-2027
6.3. Polyols
Market Estimates & Forecast, by Region, 2018-2027
Market Estimates & Forecast, by Country, 2018-2027
6.3.1. Mannitol
Market Estimates & Forecast, by Region, 2018-2027
Market Estimates & Forecast, by Country, 2018-2027
6.3.2. Sorbitol
Market Estimates & Forecast, by Region, 2018-2027
Market Estimates & Forecast, by Country, 2018-2027
6.3.3. Others
Market Estimates & Forecast, by Region, 2018-2027
Market Estimates & Forecast, by Country, 2018-2027
6.4. Carbohydrates
Market Estimates & Forecast, by Region, 2018-2027
Market Estimates & Forecast, by Country, 2018-2027
6.4.1. Sucrose
Market Estimates & Forecast, by Region, 2018-2027
Market Estimates & Forecast, by Country, 2018-2027
6.4.2. Dextrose
Market Estimates & Forecast, by Region, 2018-2027
Market Estimates & Forecast, by Country, 2018-2027
6.4.3. Starch
Market Estimates & Forecast, by Region, 2018-2027
Market Estimates & Forecast, by Country, 2018-2027
6.4.4. Others
Market Estimates & Forecast, by Region, 2018-2027
Market Estimates & Forecast, by Country, 2018-2027
7. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET, BY FORMULATION
7.1. Overview
7.2. Oral
Market Estimates & Forecast, by Region, 2018-2027
Market Estimates & Forecast, by Country, 2018-2027
7.3. Topical
Market Estimates & Forecast, by Region, 2018-2027
Market Estimates & Forecast, by Country, 2018-2027
7.4. Injectables
Market Estimates & Forecast, by Region, 2018-2027
Market Estimates & Forecast, by Country, 2018-2027
8. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET, BY REGION
8.1. Overview
8.2. North America
8.2.1. US
8.2.2. Canada
8.3. Europe
8.3.1. Germany
8.3.2. France
8.3.3. Italy
8.3.4. Spain
8.3.5. UK
8.3.6. Rest of Europe
8.4. Asia-Pacific
8.4.1. Japan
8.4.2. China
8.4.3. India
8.4.4. Australia
8.4.5. South Korea
8.4.6. Rest of Asia-Pacific
8.5. Rest of the World
8.5.1. Middle East
8.5.2. Africa
8.5.3. Latin America
9. COMPANY LANDSCAPE
9.1. Overview
9.2. Competitive Analysis
9.3. Market Share Analysis
9.4. Major Growth Strategy in the Global Biopharmaceutical Excipients Market
9.5. Competitive Benchmarking
9.6. Leading Players in terms of number of developments in the Global Biopharmaceutical Excipients Market
9.7. Key developments and Growth Strategies
9.7.1. New ProductLaunch/Service Deployment
9.7.2. Merger &Acquisitions
9.7.3. Joint Ventures
9.8. Major Players Financial Matrix
9.8.1. Sales & Operating Income, 2020
9.8.2. Major Players R&D Expenditure, 2020
10. COMPANY PROFILES
10.1. Merck KGaA
10.1.1. Company Overview
10.1.2. Product Offered
10.1.3. Financial Overview
10.1.4. Key Developments
10.1.5. SWOT Analysis
10.1.6. Key Strategies
10.2. Colorcon (BPSI Holdings Inc)
10.2.1. Company Overview
10.2.2. Products Offered
10.2.3. Financial Overview
10.2.4. Key Developments
10.2.5. SWOT Analysis
10.2.6. Key Strategies
10.3. BASF SE
10.3.1. Company Overview
10.3.2. Products Offered
10.3.3. Financial Overview
10.3.4. Key Developments
10.3.5. SWOT Analysis
10.3.6. Key Strategies
10.4. Associated British Foods plc
10.4.1. Company Overview
10.4.2. Products Offered
10.4.3. Financial Overview
10.4.4. Key Developments
10.4.5. SWOT Analysis
10.4.6. Key Strategies
10.5. Signet Excipients Pvt. Ltd (IMCD)
10.5.1. Company Overview
10.5.2. Products Offered
10.5.3. Financial Overview
10.5.4. Key Developments
10.5.5. SWOT Analysis
10.5.6. Key Strategies
10.6. Sigachi Industries Limited
10.6.1. Company Overview
10.6.2. Products Offered
10.6.3. Financial Overview
10.6.4. Key Developments
10.6.5. SWOT Analysis
10.6.6. Key Strategies
10.7. Spectrum Chemical Manufacturing Corp.
10.7.1. Company Overview
10.7.2. Products Offered
10.7.3. Financial Overview
10.7.4. Key Developments
10.7.5. SWOT Analysis
10.7.6. Key Strategies
10.8. Roquette Frères
10.8.1. Company Overview
10.8.2. Products Offered
10.8.3. Financial Overview
10.8.4. Key Developments
10.8.5. SWOT Analysis
10.8.6. Key Strategies
10.9. Clariant
10.9.1. Company Overview
10.9.2. Products Offered
10.9.3. Financial Overview
10.9.4. Key Developments
10.9.5. SWOT Analysis
10.9.6. Key Strategies
10.10. DFE Pharma
10.10.1. Company Overview
10.10.2. Products Offered
10.10.3. Financial Overview
10.10.4. Key Developments
10.10.5. SWOT Analysis
10.10.6. Key Strategies
10.11. J. Rettenmaier & Söhne GmbH + Co Kg
10.11.1. Company Overview
10.11.2. Products Offered
10.11.3. Financial Overview
10.11.4. Key Developments
10.11.5. SWOT Analysis
10.11.6. Key Strategies
10.12. Evonik Industries AG
10.12.1. Company Overview
10.12.2. Products Offered
10.12.3. Financial Overview
10.12.4. Key Developments
10.12.5. SWOT Analysis
10.12.6. Key Strategies
11. APPENDIX
11.1. References
11.2. Related Reports
?
LIST OF TABLES
TABLE 1 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SYNOPSIS, 2018-2027
TABLE 2 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET ESTIMATES &FORECAST, 2018-2027 (USD MILLION)
TABLE 3 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET, BYPRODUCT, 2018-2027 (USD MILLION)
TABLE 4 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET, BY FORMULATION, 2018-2027 (USD MILLION)
TABLE 5 NORTH AMERICA: BIOPHARMACEUTICAL EXCIPIENTS MARKET, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 6 NORTH AMERICA BIOPHARMACEUTICAL EXCIPIENTS MARKET, BY FORMULATION, 2018-2027 (USD MILLION)
TABLE 7 US: BIOPHARMACEUTICAL EXCIPIENTS MARKET, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 8 US BIOPHARMACEUTICAL EXCIPIENTS MARKET, BY FORMULATION, 2018-2027 (USD MILLION)
TABLE 9 CANADA: BIOPHARMACEUTICAL EXCIPIENTS MARKET, PRODUCT, 2018-2027 (USD MILLION)
TABLE 10 CANADA BIOPHARMACEUTICAL EXCIPIENTS MARKET, BY FORMULATION, 2018-2027 (USD MILLION)
TABLE 11 EUROPE: BIOPHARMACEUTICAL EXCIPIENTS MARKET, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 12 EUROPE BIOPHARMACEUTICAL EXCIPIENTS MARKET, BY FORMULATION, 2018-2027 (USD MILLION)
TABLE 13 GERMANY: BIOPHARMACEUTICAL EXCIPIENTS MARKET, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 14 GERMANY: BIOPHARMACEUTICAL EXCIPIENTS MARKET, BY FORMULATION, 2018-2027 (USD MILLION)
TABLE 15 FRANCE: BIOPHARMACEUTICAL EXCIPIENTS MARKET, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 16 FRANCE: BIOPHARMACEUTICAL EXCIPIENTS MARKET, FORMULATION, 2018-2027 (USD MILLION)
TABLE 17 ITALY: BIOPHARMACEUTICAL EXCIPIENTS MARKET, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 18 ITALY: BIOPHARMACEUTICAL EXCIPIENTS MARKET, BY FORMULATION, 2018-2027 (USD MILLION)
TABLE 19 SPAIN: BIOPHARMACEUTICAL EXCIPIENTS MARKET, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 20 SPAIN: BIOPHARMACEUTICAL EXCIPIENTS MARKET, BY FORMULATION, 2018-2027 (USD MILLION)
TABLE 21 UK: BIOPHARMACEUTICAL EXCIPIENTS MARKET, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 22 UK: BIOPHARMACEUTICAL EXCIPIENTS MARKET, BY FORMULATION, 2018-2027 (USD MILLION)
TABLE 23 REST OF EUROPE: BIOPHARMACEUTICAL EXCIPIENTS MARKET, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 24 REST OF EUROPE: BIOPHARMACEUTICAL EXCIPIENTS MARKET, BY FORMULATION, 2018-2027 (USD MILLION)
TABLE 25 ASIA-PACIFIC: BIOPHARMACEUTICAL EXCIPIENTS MARKET, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 26 ASIA-PACIFIC: BIOPHARMACEUTICAL EXCIPIENTS MARKET, BY FORMULATION, 2018-2027 (USD MILLION)
TABLE 27 JAPAN: BIOPHARMACEUTICAL EXCIPIENTS MARKET, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 28 JAPAN: BIOPHARMACEUTICAL EXCIPIENTS MARKET, BY FORMULATION, 2018-2027 (USD MILLION)
TABLE 29 CHINA: BIOPHARMACEUTICAL EXCIPIENTS MARKET, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 30 CHINA: BIOPHARMACEUTICAL EXCIPIENTS MARKET, BY FORMULATION, 2018-2027 (USD MILLION)
TABLE 31 INDIA: BIOPHARMACEUTICAL EXCIPIENTS MARKET, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 32 INDIA: BIOPHARMACEUTICAL EXCIPIENTS MARKET, BY FORMULATION, 2018-2027 (USD MILLION)
TABLE 33 AUSTRALIA: BIOPHARMACEUTICAL EXCIPIENTS MARKET, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 34 AUSTRALIA: BIOPHARMACEUTICAL EXCIPIENTS MARKET, FORMULATION2018-2027 (USD MILLION)
TABLE 35 SOUTH KOREA: BIOPHARMACEUTICAL EXCIPIENTS MARKET, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 36 SOUTH KOREA: BIOPHARMACEUTICAL EXCIPIENTS MARKET, BY FORMULATION2018-2027 (USD MILLION)
TABLE 37 REST OF ASIA-PACIFIC: BIOPHARMACEUTICAL EXCIPIENTS MARKET, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 38 REST OF ASIA-PACIFIC: BIOPHARMACEUTICAL EXCIPIENTS MARKET, BY FORMULATION, 2018-2027 (USD MILLION)
TABLE 39 REST OF THE WORLD: BIOPHARMACEUTICAL EXCIPIENTS MARKET, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 40 REST OF THE WORLD: BIOPHARMACEUTICAL EXCIPIENTS MARKET, FORMULATION2018-2027 (USD MILLION)
TABLE 41 MIDDLE EAST: BIOPHARMACEUTICAL EXCIPIENTS MARKET, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 42 MIDDLE EAST: BIOPHARMACEUTICAL EXCIPIENTS MARKET, FORMULATION2018-2027 (USD MILLION)
TABLE 43 AFRICA: BIOPHARMACEUTICAL EXCIPIENTS MARKET, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 44 AFRICA: BIOPHARMACEUTICAL EXCIPIENTS MARKET, BY FORMULATION2018-2027 (USD MILLION)
TABLE 45 LATIN AMERICA: BIOPHARMACEUTICAL EXCIPIENTS MARKET, BY PRODUCT, 2018-2027 (USD MILLION)
TABLE 46 LATIN AMERICA: BIOPHARMACEUTICAL EXCIPIENTS MARKET, BY FORMULATION2018-2027 (USD MILLION)
LIST OF FIGURES
FIGURE 1 RESEARCH PROCESS
FIGURE 2 MARKET STRUCTURE FOR THE GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET
FIGURE 3 MARKET DYNAMICS FOR THE GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET
FIGURE 4 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SHARE, BY PRODUCT, 2020 (%)
FIGURE 5 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SHARE, BY FORMULATION, 2020 (%)
FIGURE 6 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SHARE, BY REGION, 2020 (%)
FIGURE 7 NORTH AMERICA: BIOPHARMACEUTICAL EXCIPIENTS MARKET SHARE, BY REGION, 2020 (%)
FIGURE 8 EUROPE: BIOPHARMACEUTICAL EXCIPIENTS MARKET SHARE, BY REGION, 2020 (%)
FIGURE 9 ASIA-PACIFIC: BIOPHARMACEUTICAL EXCIPIENTS MARKET SHARE, BY REGION, 2020 (%)
FIGURE 10 REST OF THE WORLD: BIOPHARMACEUTICAL EXCIPIENTS MARKET SHARE, BY REGION, 2020 (%)
FIGURE 11 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET: COMPANY SHARE ANALYSIS, 2020 (%)
FIGURE 12 MERCK KGAA.: KEY FINANCIALS
FIGURE 13 MERCK KGAA.: SEGMENTAL REVENUE
FIGURE 14 MERCK KGAA.: REGIONAL REVENUE
FIGURE 15 COLORCON: KEY FINANCIALS
FIGURE 16 COLORCON: SEGMENTAL REVENUE
FIGURE 17 COLORCON: REGIONAL REVENUE
FIGURE 18 BASF SE: KEY FINANCIALS
FIGURE 19 BASF SE: SEGMENTAL REVENUE
FIGURE 20 BASF SE: REGIONAL REVENUE
FIGURE 21 ASSOCIATED BRITISH FOODS PLC S: KEY FINANCIALS
FIGURE 22 ASSOCIATED BRITISH FOODS PLC: SEGMENTAL REVENUE
FIGURE 23 ASSOCIATED BRITISH FOODS PLC: REGIONAL REVENUE
FIGURE 24 SIGNET EXCIPIENTS PVT. LTD (IMCD): KEY FINANCIALS
FIGURE 25 SIGNET EXCIPIENTS PVT. LTD (IMCD): SEGMENTAL REVENUE
FIGURE 26 SIGNET EXCIPIENTS PVT. LTD (IMCD): REGIONAL REVENUE
FIGURE 27 SIGACHI INDUSTRIES LIMITED: KEY FINANCIALS
FIGURE 28 SIGACHI INDUSTRIES LIMITED: SEGMENTAL REVENUE
FIGURE 29 SIGACHI INDUSTRIES LIMITED: REGIONAL REVENUE
FIGURE 30 SPECTRUM CHEMICAL MANUFACTURING CORP.: KEY FINANCIALS
FIGURE 31 SPECTRUM CHEMICAL MANUFACTURING CORP.: SEGMENTAL REVENUE
FIGURE 32 SPECTRUM CHEMICAL MANUFACTURING CORP.: REGIONAL REVENUE
FIGURE 33 ROQUETTE FRÈRES: KEY FINANCIALS
FIGURE 34 ROQUETTE FRÈRES: SEGMENTAL REVENUE
FIGURE 35 ROQUETTE FRÈRES: REGIONAL REVENUE
FIGURE 36 CLARIANT: KEY FINANCIALS
FIGURE 37 CLARIANT: SEGMENTAL REVENUE
FIGURE 38 CLARIANT: REGIONAL REVENUE
FIGURE 39 DFE PHARMA: KEY FINANCIALS
FIGURE 40 DFE PHARMA: SEGMENTAL REVENUE
FIGURE 41 DFE PHARMA: REGIONAL REVENUE
FIGURE 42 J. RETTENMAIER & SÖHNE GMBH + CO KG: KEY FINANCIALS
FIGURE 43 J. RETTENMAIER & SÖHNE GMBH + CO KG: SEGMENTAL REVENUE
FIGURE 44 J. RETTENMAIER & SÖHNE GMBH + CO KG: REGIONAL REVENUE
FIGURE 45 EVONIK INDUSTRIES AG: KEY FINANCIALS
FIGURE 46 EVONIK INDUSTRIES AG: SEGMENTAL REVENUE
FIGURE 47 EVONIK INDUSTRIES AG: REGIONAL REVENUE
